AG
Artal Group Portfolio holdings
AUM
$930M
This Quarter Return
+8.05%
1 Year Return
-3.57%
3 Year Return
+157.23%
5 Year Return
+160.22%
10 Year Return
+1,359.85%
AUM
$2.09B
AUM Growth
+$2.09B
(+4.3%)
Cap. Flow
+$237M
Cap. Flow
% of AUM
11.31%
Top 10 Holdings %
Top 10 Hldgs %
57.89%
Holding
113
New
16
Increased
20
Reduced
14
Closed
6
Top Buys
| 1 |
NVIDIA
NVDA
|
$75.4M |
| 2 |
Gossamer Bio
GOSS
|
$36M |
| 3 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$27.9M |
| 4 |
EPZM
Epizyme, Inc
EPZM
|
$21.7M |
| 5 |
BPMC
Blueprint Medicines
BPMC
|
$20M |
Top Sells
| 1 |
ARRY
Array Biopharma Inc
ARRY
|
$12.2M |
| 2 |
BLUE
bluebird bio
BLUE
|
$11.8M |
| 3 |
CMTA
Clementia Pharmaceuticals Inc.
CMTA
|
$10M |
| 4 |
AnaptysBio
ANAB
|
$9.57M |
| 5 |
argenx
ARGX
|
$8.74M |
Sector Composition
| 1 | Healthcare | 74.84% |
| 2 | Consumer Discretionary | 19.28% |
| 3 | Technology | 3.6% |
| 4 | Real Estate | 0.42% |
| 5 | Communication Services | 0.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALBO
26
DELISTED
Albireo Pharma, Inc. Common Stock
ALBO
| $16.1M | 0.66% | 500,000 | – | – |
|
|
BLUE
27
DELISTED
bluebird bio
BLUE
| $15.7M | 0.64% | 100,000 -75,000 | -43% | -$11.8M |
|
|
BOLD
28
DELISTED
Audentes Therapeutics, Inc
BOLD
| $15.6M | 0.64% | 400,000 -200,000 | -33% | -$7.8M |
|
29
Xencor
XNCR
$580M
| $15.5M | 0.63% | 500,000 | – | – |
|
30
Ascendis Pharma
ASND
$11.8B
| $14.7M | 0.6% | +125,000 | New | +$14.7M |
|
|
DRNA
31
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $14.3M | 0.59% | 979,275 +454,275 | +87% | +$6.65M |
|
|
AUTL
32
Autolus Therapeutics
AUTL
$399M
| $14.2M | 0.58% | 450,000 -25,000 | -5% | -$787K |
|
|
KLDO
33
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
| $13.7M | 0.56% | +947,419 | New | +$13.7M |
|
|
MRTX
34
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $12.8M | 0.52% | +175,000 | New | +$12.8M |
|
35
Allogene Therapeutics
ALLO
$251M
| $11.6M | 0.47% | 400,000 | – | – |
|
36
Solid Biosciences
SLDB
$427M
| $11M | 0.45% | 1,200,000 +700,000 | +140% | +$6.44M |
|
|
ZGNX
37
DELISTED
Zogenix, Inc.
ZGNX
| $11M | 0.45% | 200,000 | – | – |
|
38
FibroGen
FGEN
$47.8M
| $10.9M | 0.44% | 200,000 -100,000 | -33% | -$5.44M |
|
|
AXDX
39
DELISTED
Accelerate Diagnostics
AXDX
| $10.5M | 0.43% | 500,000 | – | – |
|
40
Krystal Biotech
KRYS
$4.27B
| $9.87M | 0.4% | 300,000 +25,000 | +9% | +$823K |
|
41
Regenxbio
RGNX
$451M
| $9.74M | 0.4% | 170,000 | – | – |
|
42
Wave Life Sciences
WVE
$1.53B
| $9.71M | 0.4% | +250,000 | New | +$9.71M |
|
43
Denali Therapeutics
DNLI
$2.23B
| $9.29M | 0.38% | 400,000 -100,000 | -20% | -$2.32M |
|
44
Replimune Group
REPL
$422M
| $9.13M | 0.37% | 600,000 +150,000 | +33% | +$2.28M |
|
45
VICI Properties
VICI
$36B
| $8.75M | 0.36% | 400,000 | – | – |
|
|
TCDA
46
DELISTED
Tricida, Inc. Common Stock
TCDA
| $8.69M | 0.35% | 225,000 +100,000 | +80% | +$3.86M |
|
|
TCRR
47
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $8.54M | 0.35% | +490,000 | New | +$8.54M |
|
|
AGEN
48
Agenus
AGEN
$133M
| $8.17M | 0.33% | 2,750,000 | – | – |
|
|
CBAY
49
DELISTED
Cymabay Therapeutics
CBAY
| $7.97M | 0.33% | 600,000 +100,000 | +20% | +$1.33M |
|
50
Spero Therapeutics
SPRO
$116M
| $7.69M | 0.31% | 600,000 | – | – |
|